CONFLICT OF INTEREST STATEMENT
Lymphoma, P., Australasian Leukaemia, Cancer
ONCOLOGY, FOX, LYMPHOMA, CANCER
Ruben A. Mesa has received research funding from AbbVie, Celgene/Bristol Myers Squibb, CTI BioPharma, Constellation, Genentech, Incyte, Promedior, Samus, and Mays Cancer Center P30 Cancer Center Support Grant from National Cancer Institutes (CA054174) and has served as a consultant for Constellation, La Jolla, Novartis, and Sierra Oncology. Stacie Hudgens and Libby Floden are employees of Clinical Outcomes Solutions, which received funding for the statistical analysis. Claire N. Harrison has received research funding from Bristol Myers Squibb, Constellation, and Novartis; has served as a speaker for AOP, AbbVie, Celgene/Bristol Myers Squibb, Constellation, CTI BioPharma, Janssen, Novartis, and Sierra Oncology; has consulted for AOP, AbbVie, CTI BioPharma, Galecto, Generon, Roche, and Sierra Oncology; has served on a data safety monitoring board or advisory board for Galecto; and has received meeting and/or travel support from Bristol Myers Squibb and Novartis. Jeanne Palmer has received research funding from CTI BioPharma, Incyte, PharmaEssentia, Protagonist Therapeutics, and Sierra Oncology and has served as an advisor for CTI BioPharma, PharmaEssentia, and Sierra Oncology. Vikas Gupta has served as a consultant for AbbVie, Celgene/Bristol Myers Squibb, Constellation, Novartis, Pfizer, and Sierra Oncology; has served as a speaker for Celgene/Bristol Myers Squibb, Constellation, and Novartis; and has served on a data safety monitoring board or advisory board for AbbVie, Celgene/Bristol Myers Squibb, Roche, and Pfizer. Donal P. McLornan has served as a speaker for AbbVie, Celgene/Bristol Myers Squibb, Jazz Pharmaceuticals, and Novartis; has received meeting and/or travel support from Jazz; and served on a data safety monitoring board or advisory board for Jazz. Mary F. McMullin has served as a speaker for AOC, AbbVie, Incyte, Novartis, and Pfizer and has received consulting fees from AbbVie, Bristol Myers Squibb, CTI BioPharma, Novartis, and Sierra Oncology. Jean‐Jaques Kiladjian has served on advisory boards or as a consultant for AOP Orphan Pharmaceuticals, Celgene/Bristol Myers Squibb, and Novartis. Lynda Foltz has served as a speaker for Celgene/Bristol Myers Squibb and Novartis Canada and served on a data safety monitoring board or advisory board for Celgene/Bristol Myers Squibb, Incite, and Novartis Canada. Uwe Platzbecker has served as a consultant for AbbVie, Celgene/Bristol Myers Squibb, Janssen, and Novartis; has served as a speaker for Amgen, Jazz, and Takeda; and has served on a data safety monitoring board or advisory board for AbbVie and Novartis. M. Laura Fox has served as a speaker for Novartis and Sierra Oncology; has received meeting and/or travel support from MDS, Novartis, and Pfizer; and served on a data safety monitoring board or advisory board for Bristol Myers Squibb, Novartis, and Sierra Oncology. Adam J. Mead has served as a consultant for AbbVie, Celgene/Bristol Myers Squibb, Galecto, Gilead, Incyte, Karyopharm, Novartis, Sensyne Health, and Sierra Oncology; has served as a speaker, received meeting and/or travel support; and participated on a data safety monitoring board or advisory board for Celgene/Bristol Myers Squibb. David M. Ross has served on advisory boards and as a speaker for Celgene/Bristol Myers Squibb, Imago, Keros, and Novartis; has received meeting and/or travel support from Novartis; has served as a consultant for Keros and Novartis; and has had an unpaid leadership role in the Australasian Leukaemia and Lymphoma Group Specialist Advisory Committee. Stephen T. Oh has served as a consultant for AbbVie, Celgene/Bristol Myers Squibb, Blueprint Medicines, Constellation, CTI BioPharma, Disc Medicine, Kartos Therapeutics, PharmaEssentia, and Sierra Oncology. Andrew Perkins has served as a speaker, received meeting and/or travel support, and served on a data safety monitoring board or advisory board for Novartis. Michael F. Leahy has nothing to disclose. Samineh Deheshi, Rafe Donahue, and Barbara J. Klencke are employees of Sierra Oncology, a GSK company. Srdan Verstovsek has received research funding from AstraZeneca, Blueprint Medicines, Celgene/Bristol Myers Squibb, CTI BioPharma, Genentech, Gilead, Incyte, Italfarmaco, Novartis, NS Pharma, Pharma Essentia, Promedior, Protagonist Therapeutics, Roche, and Sierra Oncology and has served as a consultant for Celgene/Bristol Myers Squibb, Incyte, Novartis, and Sierra Oncology.